• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » CenterWatch Monthly August 2010

CenterWatch Monthly August 2010

August 4, 2010
CenterWatch Staff

Spike in Warning Letters Sends Tremors Through Industry

The number of warning letters is increasing as the FDA ramps up enforcement efforts. The FDA is focusing more attention on data integrity and on the accountability of CROs in functional and strategic alliances. When ICON Clinical Research received a Food and Drug Administration (FDA) warning letter last November related to two antibiotic studies it had conducted for Johnson & Johnson (J&J), it sent shock waves through the industry. It was the first time the FDA cited a contract research organization (CRO) for clinical trial responsibilities delegated from a drug sponsor.

Where Business Meets Research: A Training Conundrum

Investigative site training beyond GCP—instruction focused on effective business and operating practices—is rarely available. Sponsors acknowledge that this training would improve site performance and clinical data quality, but they haven’t undertaken any organized efforts to provide it.

Eye On: Hepatitis

Infection with Hepatitis C virus (HCV) is the leading cause of chronic liver disease, with worldwide prevalence now exceeding 170 million, according to the World Health Organization. Transmission occurs through direct contact with infected blood, and complications may include cirrhosis, liver cancer (hepatocellular carcinoma; HCC) and death.Hepatitis B virus (HBV) may be transmitted through breaks in the skin, through sexual contact, and to infants born of infected mothers. Estimated worldwide prevalence of HBV infection is 2 billion, and of chronic HBV infection is 350 to 400 million, causing one million deaths annually from cirrhosis, liver failure, and HCC. Since an effective vaccine for HBV became available in the mid-1980s, incidence of acute HBV infection has markedly dropped in Western countries.

 

To read the full articles for this issue or for more information on these and other breaking stories, please click here for subscription information.

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing